MPPT – Frontiers in Medicine
New MPPT clinical study:
100% closure rate of pressure ulcers

Download Publication

Download Publication

Download Publication


Only natural ingredients

Only natural ingredients

Only natural ingredients

previous arrow
next arrow

AMR – Antimicrobial Resistance

  • The UN predicts that antibiotic-resistant infections could kill 10 million people globally by 2050.
  • Former chancellor, George Osborne in 2016 warned that apart from the consequences for human health, there will be an ‘enormous economic cost’ predicting a global reduction in GDP up to 3.5 per cent – a cumulative cost of US$100 trillion by 2050.
  • England’s CMO Dame Sally Davies says that “the threat of antibiotic resistance is as great as that from climate change and should be given as much attention from politicians and the public.”

Both antibiotics and antiseptics have been found to contribute to antimicrobial resistance (AMR). New studies by Public Health England show that antiseptics trigger tolerance mechanisms in bacteria, which cause the bacteria to become permanently resistant to both antiseptics and antibiotics and these changes occur within days, not years (Wand et al. 2017; Shepherd et al. 2018). Antiseptics therefore create resistant strains within the individual patients, leaving these patients resistant to an array of antiseptics and antibiotics. They furthermore accelerate the development and spread of resistant strains in hospitals and in the environment as these highly stable compounds often are released into nature. The compounds get into rivers, such as the Thames and the Danube via waste as well as leaks from water treatment plants, considerably increasing the risk of spread of AMR. Simultaneously, data show that they profoundly change the local ecosystem, affecting e.g. fish, invertebrates and algae.

The spread of AMR calls for the development of new antibiotics. Data indicate that the more frequently an antibiotic is used the quicker bacteria will develop resistance to it. Superior strategies to antibiotics for fighting infection in certain parts of the body have been identified and their use will consequently reduce the use of antibiotics in these conditions. Using alternative strategies will therefore be a highly effective contribution to preserving the efficacy of the antibiotics. MPPT has been proven to be superior to both antibiotics and antiseptics in the treatment of wound infections, it is effective against resistant infections and it will not contribute to AMR. It is therefore a very good example of using an alternative strategy, which will preserve the efficacy of antibiotics, which was also pointed out by the UK CMO, Dame Sally Davies regarding MPPT and how it supports the immune system:

Antimicrobial Resistance (AMR) is an escalating global threat that puts millions of lives across the world in danger. We cannot rely on the development of new antibiotics alone to mitigate this threat. We need better preventative measures as well as alternative treatments, including innovative ways to use the body’s own immune system and healthy bacteria. I am proud to say the UK are leaders in research into this area.


Bilyayeva O, Neshta VV, Golub A, Sams-Dodd F. Effects of SertaSil on wound healing in the rat. J Wound Care. 2014 Aug;23(8):410, 412-4, 415-6. doi: 10.12968/jowc.2014.23.8.410.

Bilyayeva OO, Neshta VV, Golub AA, Sams-Dodd F. Comparative Clinical Study of the Wound Healing Effects of a Novel Micropore Particle Technology: Effects on Wounds, Venous Leg Ulcers, and Diabetic Foot Ulcers. Wounds. 2017 Aug;29(8):1-9. Epub 2017 May 25.

FDA. FDA Executive Summary, Classification of Wound Dressings Combined with Drugs. Prepared for the Meeting of the General and Plastic Surgery Devices Advisory Panel. 2016; September 20-21, Page 38-39.

Guest JF, Fuller GW, Vowden P. Venous leg ulcer management in clinical practice in the UK: costs and outcomes. Int Wound J. 2018 Feb;15(1):29-37. doi: 10.1111/iwj.12814.

Guest JF, Fuller GW, Vowden P. Diabetic foot ulcer management in clinical practice in the UK: costs and outcomes. Int Wound J. 2018 Feb;15(1):43-52. doi: 10.1111/iwj.12816.

Guest JF, Fuller GW, Vowden P, Vowden KR. Cohort study evaluating pressure ulcer management in clinical practice in the UK following initial presentation in the community: costs and outcomes. BMJ Open. 2018 Jul 25;8(7):e021769. doi: 10.1136/bmjopen-2018-021769.

Guest JF, Fuller GW, Vowden P. Costs and outcomes in evaluating management of unhealed surgical wounds in the community in clinical practice in the UK: a cohort study. BMJ Open. 2018 Dec 14;8(12):e022591. doi: 10.1136/bmjopen-2018-022591.

Guest JF, Vowden K, Vowden P. The health economic burden that acute and chronic wounds impose on an average clinical commissioning group/health board in the UK. J Wound Care. 2017 Jun 2;26(6):292-303. doi: 10.12968/jowc.2017.26.6.292.

Guest JF, Ayoub N, McIlwraith T, Uchegbu I, Gerrish A, Weidlich D, Vowden K, Vowden P. Health economic burden that wounds impose on the National Health Service in the UK. BMJ Open. 2015 Dec 7;5(12):e009283. doi: 10.1136/bmjopen-2015-009283.

Guest JF, Ayoub N, McIlwraith T, Uchegbu I, Gerrish A, Weidlich D, Vowden K, Vowden P. Health economic burden that different wound types impose on the UK’s National Health Service. Int Wound J. 2017 Apr;14(2):322-330. doi: 10.1111/iwj.12603.

Lovgren M-L, Wernham A, James M, Martin-Clavijo A. Pyoderma gangrenosum ulcers treated with novel micropore particle technology. Br.J.Dermatol. 2018; 179 (Suppl. 1):BI22, p. 152.

NICE (2016) Chronic wounds: advanced wound dressings and antimicrobial dressings. NICE Guidelines

Ryan E. The use of a micropore particle technology in the treatment of acute wounds. J Wound Care. 2017 Jul 2;26(7):404-413. doi: 10.12968/jowc.2017.26.7.404.

Sams-Dodd J, Sams-Dodd F. Time to Abandon Antimicrobial Approaches in Wound Healing: A Paradigm Shift. Wounds. 2018; 30(11):345-352.

Sams-Dodd J, Sams-Dodd F. MPPT induces tissue regeneration, whereas PHMB causes degeneration, in patient. Wounds. 2019, submitted.

Shepherd MJ, Moore G, Wand ME, Sutton JM, Bock LJ. Pseudomonas aeruginosa adapts to octenidine in the laboratory and a simulated clinical setting, leading to increased tolerance to chlorhexidine and other biocides. J Hosp Infect. 2018 ;100(3):e23-e29.

Wand ME, Bock LJ, Bonney LC, Sutton JM. Mechanisms of Increased Resistance to Chlorhexidine and Cross-Resistance to Colistin following Exposure of Klebsiella pneumoniae Clinical Isolates to Chlorhexidine. Antimicrob Agents Chemother. 2016 Dec 27;61(1).

Wounds-UK (2018)

Related Posts